Introduction. Combining two medications in one bottle may improve compliance
by reducing the time required to administer drops and the frequency of the
total number of medication bottles. Objective. To compare the efficacy of
reduced intraocular pressure (IOP) and safety of fixed combination travoprost
0.004%/timolol 0.5% vs. fixed combination dorzolamide 2%/timolol 0.5% in
patients with primary open-angle glaucoma or ocular hypertension. Methods.
Prospective randomized clinical study included 60 patients divided into 2
groups. Follow-up was done at day 14 and 45 and month 3. IOP measurements
were taken at each follow-up examination at 8 am, 10 am and 4 pm. Results.
Both fixed combinations reduced IOP significantly compared to initial values
at all follow-ups (p<0.001). Mean pooled IOP at all visits and time points
was slightly lower in the travoprost/timolol group compared with the
dorzolamide/timolol group (16.13 mmHg vs. 16.15 mmHg). Mean IOP reduction
from baseline ranged from -7.46 mmHg to -9.92 mmHg in the travoprost/timolol
group and from -6.93 mmHg to -8.93 mmHg for the dorzolamide/timolol group.
Mean (?standard error of the mean) reduction in diurnal IOP from baseline to
3rd month was 8.96?2.79 in the travoprost/timolol group versus 8.07?2.91 in
patients receiving dorzolamide/timolol fixed combination (p=0.196). The most
frequent treatment-related adverse events were conjunctival hyperemia in the
travoprost/timolol group, and dry eye and foreign body sensation in the
dorzolamide/timolol group. Conclusion. Travoprost/timolol fixed combination
was slightly more effective than dorzolamide/timolol fixed combination in
reducing mean diurnal IOP. Travoprost/timolol group resulted in an IOP
reduction for up to 1.07 mmHg higher than dorzolamide/timolol group. Both
fixed combinations were well tolerated and safe.
Phase 2 Randomized Clinical Study of Netarsudil Ophthalmic Solution in Japanese Patients with Primary Open-Angle Glaucoma or Ocular Hypertension